Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Regeneron Pharmaceuticals
  6. Summary
    REGN   US75886F1075

REGENERON PHARMACEUTICALS

(REGN)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
06/16/2021 06/17/2021 06/18/2021 06/21/2021 06/22/2021 Date
523.58(c) 536.01(c) 537.92(c) 534.27(c) 534.02(c) Last
914 609 846 227 914 787 678 846 655 604 Volume
-0.74% +2.37% +0.36% -0.68% -0.05% Change
More quotes
Estimated financial data (e) (USD)
Sales 2021 12 139 M - -
Net income 2021 5 003 M - -
Net cash position 2021 10 664 M - -
P/E ratio 2021 11,7x
Yield 2021 -
Sales 2022 11 280 M - -
Net income 2022 4 096 M - -
Net cash position 2022 12 040 M - -
P/E ratio 2022 13,9x
Yield 2022 -
Capitalization 55 301 M 55 301 M -
EV / Sales 2021 3,68x
EV / Sales 2022 3,84x
Nbr of Employees 9 447
Free-Float 82,2%
More Financials
Company
Regeneron Pharmaceuticals, Inc. is a biopharmaceutical company that discovers, invents, develops, manufactures and commercializes medicines for the treatment of serious medical conditions. The Company commercializes medicines for eye diseases, high low-density lipoprotein (LDL) cholesterol, and an inflammatory condition and have product candidates in development in other areas, including rheumatoid arthritis,... 
Read more
Sector
Biotechnology & Medical Research
Calendar
06/22 | 08:00amPresentation
More about the company
Ratings of Regeneron Pharmaceuticals
Trading Rating : 
Investor Rating : 
ESG Refinitiv : 
B
More Ratings
All news about REGENERON PHARMACEUTICALS
06/22REGENERON PHARMACEUTICALS  : to Participate in Guggenheim Biopharma Strategy Ser..
PR
06/21Dual-antibody drugs effective against COVID-19 variants in animal study
RE
06/21Study confirms GSK-Vir antibody drug reduces hospitalization, death in COVID-..
RE
06/18BioNTech Doses First Patient in Mid-Stage Study of mRNA Cancer Vaccine
MT
06/18BIONTECH  : Doses First Patient in Phase 2 Trial of Vaccine Candidate in Patient..
MT
06/17REGENERON PHARMACEUTICALS  : Regen-cov phase 3 recovery trial meets primary outc..
AQ
06/17EMEA MORNING BRIEFING  : Fed's Surprise Hawkish -2-
DJ
06/16Healthcare Shares Slip but Beat the Broader Market -- Health Care Roundup
DJ
06/16REGENERON PHARMACEUTICALS, INC.  : Submission of Matters to a Vote of Security H..
AQ
06/16REGENERON PHARMACEUTICALS  : Phase 3 Study Shows REGEN-COV Reduces Death Risk in..
MT
06/16STUDY : Antibody cocktail by Regeneron cuts COVID-19 death risk by 20%
AQ
06/16WALL STREET STOCK EXCHANGE : How yesterday’s data could affect Fed policy
06/16EUROPEAN MIDDAY BRIEFING  : Investors Pause With -2-
DJ
06/16ROCHE  : Regeneron COVID-19 Antibody Cocktail Reduces Death Risk in Late-Stage T..
MT
06/16REGENERON PHARMACEUTICALS  : Says REGEN-COV Improves Survival Rate in Hospitaliz..
MT
More news
News in other languages on REGENERON PHARMACEUTICALS
06/16WALL STREET STOCK EXCHANGE : Wall Street lager gesloten na rentebesluit Fed
06/16WALL STREET STOCK EXCHANGE : Wall Street koerst af op lager slot
06/16WALL STREET STOCK EXCHANGE : Cómo podrían afectar los datos de ayer a la polític..
06/16WALL STREET STOCK EXCHANGE : Verdeelde start Wall Street in de maak
06/16WALL STREET STOCK EXCHANGE : Futures wijzen op vlakke start Wall Street
More news
Analyst Recommendations on REGENERON PHARMACEUTICALS
More recommendations
Analysis
Bank of America poaches Citi's Regniez to co-head France investment banking
Chart REGENERON PHARMACEUTICALS
Duration : Period :
Regeneron Pharmaceuticals Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends REGENERON PHARMACEUTICALS
Short TermMid-TermLong Term
TrendsBullishNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 25
Last Close Price 534,02 $
Average target price 621,64 $
Spread / Average Target 16,4%
EPS Revisions
Managers and Directors
NameTitle
Leonard S. Schleifer Co-President, Chief Executive Officer & Director
George Damis Yancopoulos Co-President, Director & Chief Scientific Officer
Robert E. Landry Chief Financial Officer & Executive VP-Finance
P. Roy Vagelos Chairman
Neil Stahl Executive VP-Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
REGENERON PHARMACEUTICALS10.54%55 301
GILEAD SCIENCES, INC.15.09%84 469
WUXI APPTEC CO., LTD.24.70%66 143
BIONTECH SE190.10%54 605
VERTEX PHARMACEUTICALS-20.09%48 589
BEIGENE, LTD.28.69%30 138